For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 31,437 | 20,835* | 28,773 | 30,549 |
| General and administrative | 8,182 | 8,567* | 7,898 | 8,515 |
| Total operating expenses | 39,619 | 29,401 | 36,671 | 39,064 |
| Loss from operations | -39,619 | -29,401* | -36,671 | -39,064 |
| Other income, net | 3,852 | 3,347* | 4,084 | 2,709 |
| Net loss | -35,767 | -26,055* | -32,587 | -36,355 |
| Unrealized gain on investments | -1,076 | -202* | 428 | -22 |
| Comprehensive loss | -36,843 | -26,257 | -32,159 | -36,377 |
| Basic EPS | -0.34 | -0.304 | -0.33 | -0.47 |
| Diluted EPS | -0.34 | -0.304 | -0.33 | -0.47 |
| Basic Average Shares | 105,472,766 | 86,301,815 | 98,953,331 | 78,126,257 |
| Diluted Average Shares | 105,472,766 | 86,301,815 | 98,953,331 | 78,126,257 |
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)